Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites. - Wikidata - wikimedia - TriplyDB

Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites.

Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites.

http://www.wikidata.org/entity/Q43040568

about

Alcohol use, viral hepatitis and liver fibrosis among HIV-positive persons in West Africa: a cross-sectional study.Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA.Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.Diagnostic accuracy of point-of-care tests for hepatitis C virus infection: a systematic review and meta-analysis Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease.Comparison of Rapid Point-of-Care Tests for Detection of Antibodies to Hepatitis C Virus.HIV infection, viral hepatitis and liver fibrosis among prison inmates in West Africa Absence of Active Hepatitis C Virus Infection in Human Immunodeficiency Virus Clinics in Zambia and Mozambique.Point-of-care testing for sexually transmitted infections: recent advances and implications for disease control Performance evaluation of the OraQuick hepatitis C virus rapid antibody test Hepatitis C in HIV-infected individuals: a systematic review and meta-analysis of estimated prevalence in Africa.Diagnostic Performance of Two Point-of-Care Tests for Anti-HCV Detection.Successful Integration of Hepatitis C Virus Point-of-Care Tests into the Denver Metro Health Clinic.The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging.Laboratory diagnostics for hepatitis C virus infection.Rapid diagnostic HCV antibody assays.Hepatitis C virus: a silent killer relevant to dentistry.Hepatitis C and HIV Coinfection for Social Workers in Public Health, Medical and Substance Use Treatment Settings.Direct-acting antiviral agents for HCV infection affecting people who inject drugs.Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.Evaluation of two rapid screening assays for detecting hepatitis C antibodies in resource-constrained settings.Multiplexed testing for HIV and related bacterial and viral co-infections at the point-of-care: quo vadis?HCV Health Policy Developments in Response to the National Viral Hepatitis Action Plan: A Brief Update.Schnelltest-Diagnostik sexuell übertragbarer Infektionen in niedrigschwelligen Einrichtungen : Gemeinsame Stellungnahme des RKI, PEI und der DSTIG.Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature.Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis.Hepatitis C Virus Screening: A Review of the OraQuick Hepatitis C Virus Rapid Antibody Test.Incorporation of Social Determinants of Health in the Peer-Reviewed Literature: A Systematic Review of Articles Authored by the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

P2860

Q33787607-8DE11A25-0C14-45B0-88E1-E6021208AA01 Q33834953-A7940921-290C-4640-82D2-46A424DC5CE4 Q34008754-398F38F8-E657-45F7-8804-37A500421047 Q35224772-57758DD5-9618-41E4-A474-FC07097D18CF Q35237341-6E3008EC-BE34-4E12-9A01-30274FFB1FD4 Q35935659-EB4E5534-BF9F-4D62-9E6B-8662DF6A4252 Q36042246-F293272E-7DCF-4A9B-BA89-11EEC8D435FC Q36754781-729B63E4-2836-4084-85A3-A9272EB8729F Q36792243-2F90AFB7-17DF-458C-8F99-9A6F6C8A21AD Q36821811-E7400FEA-CD81-43B7-B75E-4B1C5D201300 Q36995882-C95EC997-8B4F-48B4-BBF6-047F08BEE88D Q37315188-D758AEBA-A52D-44A9-844D-14F9983E6961 Q37435745-6614F868-2878-4373-A4B9-08D3DA9657C5 Q37455611-2F36A5E8-D3C0-444F-87ED-F91E0E50DB87 Q37682493-A40F4BB7-EB8F-4F92-AE4D-67583882E13E Q38020158-C5FFFCEF-580F-4F6D-9CEF-969D5C952B74 Q38074389-5A1079A7-C878-4EF9-8240-CEF805A4D65B Q38199205-A0A0240A-335D-44D0-AF69-B58DD34D04E0 Q38391718-7E17BEDC-6CF1-4616-B41A-F4BF0629B702 Q38613271-730DFE62-EDBD-4DB7-995B-37BB02AE4EB8 Q38661825-9C19BBDC-B292-41AB-A55D-057CCD415CAC Q39945743-C691958F-B168-4DFE-86E3-FDFC35F34E21 Q41400740-CF50BA0F-F70E-4A68-8A5F-B1EB7FCF2408 Q42050428-7D0C39C0-4E06-434E-A3C5-8858FD370AE3 Q45030352-48EE3F3D-918A-45EA-A8B3-24DD4CFD208B Q45191773-14D5A030-6253-46D8-A4A4-8B8430437DE7 Q47594606-6CB5FB88-EDEC-456B-A380-528876EE8005 Q55397427-2D7B72B7-52C9-4D8B-8A98-639E578CD7C5 Q57178901-000EDE54-04E7-4370-8B81-7D675AE9B7AF

P2860

Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites.

http://www.wikidata.org/entity/Q43040568

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Performance of premarket rapid ...... ral surveillance system sites.

@en

Performance of premarket rapid ...... ral surveillance system sites.

@nl

type

label

Performance of premarket rapid ...... ral surveillance system sites.

@en

Performance of premarket rapid ...... ral surveillance system sites.

@nl

prefLabel

Performance of premarket rapid ...... ral surveillance system sites.

@en

Performance of premarket rapid ...... ral surveillance system sites.

@nl

P1433

Q43040568-8483D6BE-691C-4FE9-812A-28CD978E1290

P1476

Q43040568-2B783F0E-5F03-49AC-8C7A-08C7A57F16DB

P2093

Q43040568-16CF6A0A-A1F7-4C38-B4A7-C19DF4CF549B

Q43040568-5DFD21FB-E806-453B-AD7E-15BF0C98F097

Q43040568-6A693936-CDB0-4E12-8C55-0D8363142B5E

Q43040568-6B3DD105-0977-4A0B-BA9B-6441DAB11129

Q43040568-7978C69E-7A26-48C8-BC22-41DDB5A7AAA5

Q43040568-7C6B89AC-7C60-4653-9D17-2D8886EA7838

Q43040568-9F806371-062D-4A59-9E93-7A939F454DF4

Q43040568-AB139A6F-3906-4FBD-957D-49E1B6D8C4AC

Q43040568-B4367DE4-87BA-4816-A290-2F3CD2E7D11A

Q43040568-B925230E-E15C-45EF-B419-63774B5165A5

P2860

Q43040568-0A819497-5382-47CC-B828-3605EC81C41C

Q43040568-0B9F9701-184C-4A66-A5FB-C4C1A4A640BB

Q43040568-1A323858-5E60-4E33-8FF3-AC917E02EF11

Q43040568-21A51CCC-F4EF-42A2-8D68-00EE2ABDD104

Q43040568-35718D23-3A8E-4AE7-9B57-53C0052D691B

Q43040568-39613004-AFA8-45B2-814A-2E0426890C4B

Q43040568-58746D0D-7A10-4501-AD1C-4AB1F6B8C693

Q43040568-5C645F78-0E59-45F6-BDE5-03A8E29B9D0D

Q43040568-5F0186FC-DC4F-47A2-9D3B-2E7B9C70AEAE

Q43040568-70741AEE-1816-4B2E-BE9F-24151504142E

P304

Q43040568-40ED2F79-22F9-4E75-8A04-00F9960BBDE0

P31

Q43040568-1C2E6679-A364-4788-A155-17B1FA08F874

P356

Q43040568-2D7D8F27-494B-4861-B90B-04A68F63D90B

P407

Q43040568-376C5606-4463-44FD-924E-EC8AE96DED8E

P433

Q43040568-070BEBE3-6A0B-4FB2-B275-324B25F2019E

P478

Q43040568-77EB22C8-B03F-4348-AE26-137676BE62C3

P577

Q43040568-5F939B14-3A42-4A5D-A3BB-15A16DC98D6C

P5875

Q43040568-B40FB4A3-2ED3-4902-B5B3-FCD1724433C4

P698

Q43040568-2F390D73-6716-455E-BC2D-E1E35EE947CE

P921

Q43040568-DB1FF01C-D9DD-45D9-81AA-8AB7EBF5F057

P356

P1433

Clinical Infectious Diseases

P1476

Performance of premarket rapid ...... ral surveillance system sites.

@en

P2093

Alan Neaigus

http://www.w3.org/2001/XMLSchema#string

Alexa M Oster

http://www.w3.org/2001/XMLSchema#string

Alia Al-Tayyib

http://www.w3.org/2001/XMLSchema#string

Amanda Smith

http://www.w3.org/2001/XMLSchema#string

Amy Jewett

http://www.w3.org/2001/XMLSchema#string

Bryce D Smith

http://www.w3.org/2001/XMLSchema#string

Cindy M Weinbaum

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Dinenno

http://www.w3.org/2001/XMLSchema#string

Eyasu Teshale

http://www.w3.org/2001/XMLSchema#string

Hanne Thiede

http://www.w3.org/2001/XMLSchema#string

P2860

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare setting.

Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting.

HIV prevalence rates among injection drug users in 96 large US metropolitan areas, 1992-2002.

Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program.

Relative efficacy of prevention counseling with rapid and standard HIV testing: a randomized, controlled trial (RESPECT-2).

Rapid hiv testing in urban outreach: a strategy for improving posttest counseling rates.

Outcomes of offering rapid point-of-care HIV testing in a sexually transmitted disease clinic.

Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004.

Poor sensitivity of field rapid HIV testing: implications for mother-to-child transmission programme.

P304

780-786

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIR499

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51645977

http://www.w3.org/2001/XMLSchema#string

P698

21921221

http://www.w3.org/2001/XMLSchema#string

P921